NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/14/2023
Back to search
Official data from USPTO
COAVE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
COAVE THERAPEUTICS
ST13
US500000097197299Class
5, 42
Filing
97197299
Registration
6999420
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
03/14/2023
Trademark type
Word
Nice classes
5, 42
Filing date
12/30/2021
Registration date
03/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/14/2023
Last transaction
03/14/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Paris, FR
Examiner
BRACEY, KAREN
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
C. T. (pessoa física)
Representatives
Pina Campagna CARTER, DELUCA AND FARRELL LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations in the nature of viral systemsgene therapy systemsnucleic acid delivery systems comprised of viral vectorsgene therapy vectorsnucleic acid delivery vectorscells used to deliver modified genetic material into other cells for medical purposes for the diagnosistreatment or prevention of ophthalmological disordersdiseases of the central and peripheral nervous systemhereditary disordersgenetic disorders and disorders of monogenic origin; Pharmaceutical preparations and products in the nature of genetically modified cells for use in gene therapy for medical purposes; Pharmaceutical preparationsvaccinesprophylactic pharmaceuticals in the nature of antigensother genetically modified pharmaceuticals cells or tissue for use in nucleic acid therapygene therapy and cell therapy; Drug delivery agents in the nature genetically modified compounds for medicalpharmaceutical or veterinary purposes; Biological tissue cultures for medical purposes; Chemical or biological reagents for medicalpharmaceutical or veterinary purposesfor nucleic acid therapygene therapy and cell therapy; Biological preparations for medicalpharmaceutical or veterinary purposesfor use in connection with medical and clinical gene therapynucleic acid therapy and cell therapy to diagnosetreat and prevent ophthalmological disordersdiseases of the central and peripheral nervous systemhereditary disordersgenetic disorders and disorders of monogenic origin
Class 42
Product research and development in the fields of biotechnologybiologybiomedicinepharmacymedical sciencesgene therapychemistry and biochemistry; Biologicalbiomedical and pharmaceutical therapeutic research services; Research in the fields of pharmaceutical and biological therapeutic preparationsgene therapy and nucleic acid delivery systems for use in clinical trials and post-marketing trials; Pharmaceutical research and development; Provision of scientific research information in the fields of pharmaceuticalsbiomedicinegene therapyclinical trials and post-marketing trials; Biological research; Chemical analysis and research services; Providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others; Medical research services
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/14/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/27/2022
PUBO
PUBLISHED FOR OPPOSITION
12/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/22/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/21/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/21/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2022
GNRT
NON-FINAL ACTION E-MAILED
10/04/2022
CNRT
NON-FINAL ACTION WRITTEN
10/04/2022
DOCK
ASSIGNED TO EXAMINER
10/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/05/2022
NWAP
NEW APPLICATION ENTERED
01/03/2022
Continuous trademark protection
Get notified about every new filing that threatens COAVE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.